Publications

For a complete list of publications, refer to PubMed.

2024

  • Childhood Maltreatment and Leukocyte Telomere Length: Cardiac Vagal Activity Influences the Relation in Older Adults. Connor, A., Deschamps, A., Busque, L., Tardif, J. C., Bourgoin, V., Dubé, M. P., Busseuil, D. and D'Antono, B. Psychosom. Med. 2024; 3: 146-156. [BibTeX]
  • The Relationship Between Perceived Parenting Practices and Anxiety in Adults With Congenital Heart Disease. Houchi, C., Marcil, M. J., Nadarajah, K., Mageau, G. A, Khairy, P., Marin, M. F., Cossette, M., Dubé, M. P., Chaix, M. A., Mongeon, F. P., Dore, A., Mondésert, B., Ibrahim, R.; and Brouillette, J. Can. J. Cardiol. 2024. [BibTeX]
  • Meta-Analysis of Genome-Wide Association Studies Reveals Genetic Mechanisms of Supraventricular Arrhythmias. Weng, L. C., Khurshid, S., Hall, A. W., Nauffal, V., Morrill, V. N., Sun, Y. V., Rämö, J. T., Beer, D., Lee, S., Nadkarni, G., Johnson, R., Andreasen, L., Clayton, A., Pullinger, C. R., Yoneda, Z. T., Friedman, D. J., Hyman, M. C., Judy, R. L., Skanes, A. C., Orland, K. M., Jordà, P., Treu, T. M., Oetjens, M. T., Subbiah, R., Hartmann, J. P., May, H. T., Kane, J. P., Issa, T. Z., Nafissi, N. A., Leong-Sit, P. et al. Circ. Genom. Precis. Med. 2024; 3: e004320. [BibTeX]
  • A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol. Meloche, M., Pilon, M. O., Provost, S., Leclair, G., Oussaïd, E., St-Jean, I., Jutras, M., Gaulin, M. J., Lemieux-Perreault, L. P., Valois, D., Mongrain, I., Busseuil, D., Rouleau, J. L., Tardif, J. C., Dubé, M. P. and de Denus, S. J. Pers. Med. 2024; 6: 649. [BibTeX]
  • Prediction of incident atrial fibrillation using deep learning, clinical models and polygenic scores. Jabbour, G., Nolin-Lapalme, A., Tastet, O., Corbin, D., Jordà, P., Sowa, A., Delfrate, J., Busseuil, D., Hussin, J., Dubé, M. P., Tardif, J. C., Rivard, L., Macle, L., Cadrin-Tourigny, J., Khairy, P., Avram, R. and Tadros, R. Eur. Heart J. 2024: ehae595. [BibTeX]

2023

  • Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors. Sun, M., Cyr, M. C., Sandoval, J., Lemieux Perreault, L. P., Busque, L., Tardif, J. C. and Dubé, M. P. Cancer Epidemiol Biomarkers Prev 2023; 6: 776-783. [BibTeX]
  • Study of effect modifiers of genetically predicted CETP reduction. Legault, M. A., Barhdadi, A., Gamache, I., Lemaçon, A., Lemieux Perreault, L. P., Grenier, J. C., Sylvestre, M. P., Hussin, J. G., Rhainds, D., Tardif, J. C. and Dubé, M. P. Genet Epidemiol 2023; 2: 198-212. [BibTeX]
  • GAA Repeat Expansion in Late-Onset Cerebellar Ataxia. Pellerin, D., Danzi, M. C., Wilke, C., Renaud, M., Fazal, S., Dicaire, M. J., Scriba, C. K., Ashton, C., Yanick, C., Beijer, D., Rebelo, A., Rocca, C., Jaunmuktane, Z., Sonnen, J. A., Larivière, R., Genis, D., Molina Porcel, L., Choquet, K., Sakalla, R., Provost, S., Robertson, R., Allard-Chamard, X., Thétreault, M., Reiling, S. J., Nagy, S., Nishadham, V., Purushottam, M., Vengalil, S., Bardhan, M., Nalini, A. et al. N Engl J Med 2023; 2: 128-141. [BibTeX]
  • Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signalling involved in atheroprotection. Rautureau, Y., Berlatie, M., Rivas, D., Uy, K., Blanchette, A., Miquel, G., Higgins, È., Mecteau, M., Nault, A., Villeneuve, L., Lavoie, V., berge-Julien, G., Brand, G., Lapointe, L., Denis, M., Rosa, C., Fortier, A., Blondeau, L., Guertin, M. C., é, M. P., Thorin, É., Ledoux, J., Rhainds, D., aume, É. and Tardif, J. C. Cardiovasc Res 2023; 2: 450-464. [BibTeX]
  • -OH-metoprolol concentrations: a genome-wide association study. re, J., Meloche, M., Provost, S., Leclair, G., d, E., Jutras, M., Perreault, L. L., Valois, D., Mongrain, I., Busseuil, D., Rouleau, J. L., Tardif, J. C., é, M. P. and Denus, S. Pharmacogenomics 2023; 8: 441-448. [BibTeX]
  • Females present higher dose-adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males. Hindi, J., Pilon, M. O., Meloche, M., Leclair, G., d, E., St-Jean, I., Jutras, M., Gaulin, M. J., Mongrain, I., Busseuil, D., Rouleau, J. L., Tardif, J. C., é, M. P. and de Denus, S. Clin Transl Sci 2023; 5: 872-885. [BibTeX]
  • Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals. Gagnon, M. F., Provost, S., Sun, M., Ayachi, S., Buscarlet, M., Mollica, L., Szuber, N., é, M. P. and Busque, L. Blood Adv 2023; 13: 3232-3243. [BibTeX]
  • A dataset of proteomic changes during human heat stress and heat acclimation. Gagnon, D., Barry, H., Barhdadi, A., Oussaid, E., Mongrain, I., Lemieux Perreault, L. P. and é, M. P. Sci Data 2023; 1: 877. [BibTeX]
  • -OH-metoprolol concentrations, metoprolol dosing and heart rate: A cross-sectional study. Robert, S., Pilon, M. O., d, E., Meloche, M., Leclair, G., Jutras, M., Gaulin, M. J., Mongrain, I., Busseuil, D., Tardif, J. C., é, M. P. and de Denus, S. Pharmacol Res Perspect 2023; 5: e01137. [BibTeX]

2022

  • Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome. Tardif, J. C., Pfeffer, M. A. and Dubé, M. P. Eur Heart J 2022; 48: 5062-5063. [BibTeX]
  • Do variants in the coding regions of FOXP2, a gene implicated in speech disorder, confer a risk for congenital amusia?. Peretz, I., Ross, J., Bourassa, C. V., Perreault, L. L., Dion, P. A., Weiss, M. W., Felezeu, M., Rouleau, G. A. and Dubé, M. P. Ann N Y Acad Sci 2022; 1: 279-285. [BibTeX]
  • Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Tardif, J. C., Pfeffer, M. A., Kouz, S., Koenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., Waters, D. D., Grégoire, J. C., L'Allier, P. L., Wouter Jukema, J., White, H. D., Heinonen, T., Black, D. M., Laghrissi-Thode, F., Levesque, S., Guertin, M. C. and Dubé, M. P. Eur Heart J 2022; 39: 3947-3956. [BibTeX]
  • Including diverse and admixed populations in genetic epidemiology research. Caliebe, A., Tekola-Ayele, F., Darst, B. F., Wang, X., Song, Y. E., Gui, J., Sebro, R. A., Balding, D. J., Saad, M. and Dubé, M. P. Genet Epidemiol 2022; 7: 347-371. [BibTeX]
  • Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. Dubé, M. P., Chazara, O., Lemaçon, A., Asselin, G., Provost, S., Barhdadi, A., Lemieux Perreault, L. P., Mongrain, I., Wang, Q., Carss, K., Paul, D. S., Cunningham, J. W., Rouleau, J., Solomon, S. D., McMurray, J. J. V., Yusuf, S., Granger, C. B., Haefliger, C., de Denus, S. and Tardif, J. C. ESC Heart Fail 2022; 5: 2997-3008. [BibTeX]
  • Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. Sun, M., Dubé, M. P., Hennessy, T., Schultz, C. J., Barhdadi, A., Rhainds, D., Hillis, G. S. and Tardif, J. C. Int J Cardiol 2022: 20-22. [BibTeX]
  • An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites. Pilon, M. O., Leclair, G., Oussaïd, E., St-Jean, I., Jutras, M., Gaulin, M. J., Mongrain, I., Busseuil, D., Rouleau, J. L., Tardif, J. C., Dubé, M. P. and de Denus, S. Clin Transl Sci 2022; 8: 2024-2034. [BibTeX]
  • Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Cadby, G., Giles, C., Melton, P. E., Huynh, K., Mellett, N. A., Duong, T., Nguyen, A., Cinel, M., Smith, A., Olshansky, G., Wang, T., Brozynska, M., Inouye, M., McCarthy, N. S., Ariff, A., Hung, J., Hui, J., Beilby, J., Dubé, M. P., Watts, G. F., Shah, S., Wray, N. R., Lim, W. L. F., Chatterjee, P., Martins, I., Laws, S. M., Porter, T., Vacher, M., Bush, A. I., Rowe, C. C. et al. Nat Commun 2022; 1: 3124. [BibTeX]
  • Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signaling involved in atheroprotection. Rautureau, Y., Berlatie, M., Rivas, D., Uy, K., Blanchette, A., Miquel, G., Higgins, È., Mecteau, M., Nault, A., Villeneuve, L., Lavoie, V., Théberge-Julien, G., Brand, G., Lapointe, L., Denis, M., Rosa, C., Fortier, A., Blondeau, L., Guertin, M. C., Dubé, M. P., Thorin, É., Ledoux, J., Rhainds, D., Rhéaume, É. and Tardif, J. C. Cardiovasc Res 2022. [BibTeX]
  • ExPheWas: a platform for cis-Mendelian randomization and gene-based association scans. Legault, M. A., Perreault, L. L., Tardif, J. C. and Dubé, M. P. Nucleic Acids Res 2022; W1: W305-311. [BibTeX]
  • Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study. Meloche, M., Leclair, G., Jutras, M., Oussaïd, E., Gaulin, M. J., Mongrain, I., Busseuil, D., Tardif, J. C., Dubé, M. P. and de Denus, S. Clin Transl Sci 2022; 4: 1063-1073. [BibTeX]
  • Construction of a femininity score in the UK Biobank and its association with angina diagnosis prior to myocardial infarction. Levinsson, A., de Denus, S., Sandoval, J., Lemieux Perreault, L. P., Rouleau, J., Tardif, J. C., Hussin, J. and Dubé, M. P. Sci Rep 2022; 1: 1780. [BibTeX]
  • Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Perreault, S., Dragomir, A., Côté, R., Lenglet, A., de Denus, S., Dorais, M., White-Guay, B., Brophy, J., Schnitzer, M. E., Dubé, M. P. and Tardif, J. C. Front Pharmacol 2021: 812018. [BibTeX]
  • Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19. Tardif, J. C., Cossette, M., Guertin, M. C., Bouabdallaoui, N., Dubé, M. P. and Boivin, G. Int J Infect Dis 2022: 387-390. [BibTeX]

2021

  • A sex-specific evolutionary interaction between ADCY9 and CETP. Gamache, I., Legault, M. A., Grenier, J. C., Sanchez, R., Rhéaume, E., Asgari, S., Barhdadi, A., Zada, Y. F., Trochet, H., Luo, Y., Lecca, L., Murray, M., Raychaudhuri, S., Tardif, J. C., Dubé, M. P. and Hussin, J. Elife 2021. [BibTeX]
  • The genomics of heart failure: design and rationale of the HERMES consortium. Lumbers, R. T., Shah, S., Lin, H., Czuba, T., Henry, A., Swerdlow, D. I., Mälarstig, A., Andersson, C., Verweij, N., Holmes, M. V., Ärnlöv, J., Svensson, P., Hemingway, H., Sallah, N., Almgren, P., Aragam, K. G., Asselin, G., Backman, J. D., Biggs, M. L., Bloom, H. L., Boersma, E., Brandimarto, J., Brown, M. R., Brunner-La Rocca, H. P., Carey, D. J., Chaffin, M. D., Chasman, D. I., Chazara, O., Chen, X., Chen, X. et al. ESC Heart Fail 2021; 6: 5531-5541. [BibTeX]
  • Multitrait GWAS to connect disease variants and biological mechanisms. Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Nerin, C., Vaysse, A., Lechat, P., Ménager, H., Le Goff, W., Dube, M. P., Kraft, P., Ionita-Laza, I., Vilhjálmsson, B. J. and Aschard, H. PLoS Genet 2021; 8: e1009713. [BibTeX]
  • Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Tardif, J. C., Bouabdallaoui, N., L'Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., Lopez-Sendon, J., da Luz, P., Verret, L., Audet, S., Dupuis, J., Denault, A., Pelletier, M., Tessier, P. A., Samson, S., Fortin, D., Tardif, J. D., Busseuil, D., Goulet, E., Lacoste, C., Dubois, A., Joshi, A. Y., Waters, D. D., Hsue, P., Lepor, N. E., Lesage, F., Sainturet, N., Roy-Clavel, E., Bassevitch, Z., Orfanos, A. et al. Lancet Respir Med 2021; 8: 924-932. [BibTeX]
  • Genetics of symptom remission in outpatients with COVID-19. Dubé, M. P., Lemaçon, A., Barhdadi, A., Lemieux Perreault, L. P., Oussaïd, E., Asselin, G., Provost, S., Sun, M., Sandoval, J., Legault, M. A., Mongrain, I., Dubois, A., Valois, D., Dedelis, E., Lousky, J., Choi, J., Goulet, E., Savard, C., Chicoine, L. M., Cossette, M., Chabot-Blanchet, M., Guertin, M. C., de Denus, S., Bouabdallaoui, N., Marchand, R., Bassevitch, Z., Nozza, A., Gaudet, D., L'Allier, P. L., Hussin, J. et al. Sci Rep 2021; 1: 10847. [BibTeX]
  • Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. Rhainds, D., Packard, C. J., Brodeur, M. R., Niesor, E. J., Sacks, F. M., Jukema, J. W., Wright, R. S., Waters, D. D., Heinonen, T., Black, D. M., Laghrissi-Thode, F., Dubé, M. P., Pfeffer, M. A. and Tardif, J. C. Circ Genom Precis Med 2021; 2: e003219. [BibTeX]
  • Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Schunk, S. J., Kleber, M. E., März, W., Pang, S., Zewinger, S., Triem, S., Ege, P., Reichert, M. C., Krawczyk, M., Weber, S. N., Jaumann, I., Schmit, D., Sarakpi, T., Wagenpfeil, S., Kramann, R., Boerwinkle, E., Ballantyne, C. M., Grove, M. L., Tragante, V., Pilbrow, A. P., Richards, A. M., Cameron, V. A., Doughty, R. N., Dubé, M. P., Tardif, J. C., Feroz-Zada, Y., Sun, M., Liu, C., Ko, Y. A., Quyyumi, A. A. et al. Eur Heart J 2021; 18: 1742-1756. [BibTeX]
  • Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. Sun, M., Lemaçon, A., Legault, M. A., Asselin, G., Provost, S., Aschard, H., Barhdadi, A., Zada, Y. F., Valois, D., Mongrain, I., Tardif, J. C. and Dubé, M. P. Pharmacogenomics J 2021; 4: 446-457. [BibTeX]
  • Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. Dubé, M. P., Legault, M. A., Lemaçon, A., Lemieux Perreault, L. P., Fouodjio, R., Waters, D. D., Kouz, S., Pinto, F. J., Maggioni, A. P., Diaz, R., Berry, C., Koenig, W., Lopez-Sendon, J., Gamra, H., Kiwan, G. S., Asselin, G., Provost, S., Barhdadi, A., Sun, M., Cossette, M., Blondeau, L., Mongrain, I., Dubois, A., Rhainds, D., Bouabdallaoui, N., Samuel, M., de Denus, S., L'Allier, P. L., Guertin, M. C., Roubille, F. et al. Circ Genom Precis Med 2021; 2: e003183. [BibTeX]
  • Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. Perreault, S., Dragomir, A., Côté, R., Lenglet, A., White-Guay, B., de Denus, S., Schnitzer, M. E., Dubé, M. P., Brophy, J. M., Dorais, M. and Tardif, J. C. Pharmacotherapy 2021; 4: 379-393. [BibTeX]
  • Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Tadros, R., Francis, C., Xu, X., Vermeer, A. M. C., Harper, A. R., Huurman, R., Kelu Bisabu, K., Walsh, R., Hoorntje, E. T., Te Rijdt, W. P., Buchan, R. J., van Velzen, H. G., van Slegtenhorst, M. A., Vermeulen, J. M., Offerhaus, J. A., Bai, W., de Marvao, A., Lahrouchi, N., Beekman, L., Karper, J. C., Veldink, J. H., Kayvanpour, E., Pantazis, A., Baksi, A. J., Whiffin, N., Mazzarotto, F., Sloane, G., Suzuki, H., Schneider-Luftman, D., Elliott, P. et al. Nat Genet 2021; 2: 128-134. [BibTeX]
  • The associations of hostility and defensiveness with telomere length are influenced by sex and health status. Starnino, L., Dupuis, G., Busque, L., Bourgoin, V., Dubé, M. P., Busseuil, D. and D'Antono, B. Biol Sex Differ 2021; 1: 2. [BibTeX]
  • Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Samuel, M., Tardif, J. C., Bouabdallaoui, N., Khairy, P., Dubé, M. P., Blondeau, L. and Guertin, M. C. Can J Cardiol 2021; 5: 776-785. [BibTeX]
  • Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. Kassem, I., Sanche, S., Li, J., Bonnefois, G., Dubé, M. P., Rouleau, J. L., Tardif, J. C., White, M., Turgeon, J., Nekka, F. and de Denus, S. Clin Transl Sci 2021; 1: 194-203. [BibTeX]
  • Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Samuel, M., Tardif, J. C., Khairy, P., Roubille, F., Waters, D. D., Grégoire, J. C., Pinto, F. J., Maggioni, A. P., Diaz, R., Berry, C., Koenig, W., Ostadal, P., Lopez-Sendon, J., Gamra, H., Kiwan, G. S., Dubé, M. P., Provencher, M., Orfanos, A., Blondeau, L., Kouz, S., L'Allier, P. L., Ibrahim, R., Bouabdallaoui, N., Mitchell, D., Guertin, M. C. and Lelorier, J. Eur Heart J Qual Care Clin Outcomes 2021; 5: 486-495. [BibTeX]
  • Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Perreault, S., Dragomir, A., Côté, R., Lenglet, A., de Denus, S., Dorais, M., White-Guay, B., Brophy, J., Schnitzer, M. E., Dubé, M. P. and Tardif, J. C. Front Pharmacol 2021: 812018. [BibTeX]

2020

  • A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy. de Denus, S., Mottet, F., Korol, S., Feroz Zada, Y., Provost, S., Mongrain, I., Asselin, G., Oussaïd, E., Busseuil, D., Lettre, G., Rioux, J., Racine, N., O'Meara, E., White, M., Rouleau, J., Tardif, J. C. and Dubé, M. P. ESC Heart Fail 2020. [BibTeX]
  • Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Bouabdallaoui, N., Tardif, J. C., Waters, D. D., Pinto, F. J., Maggioni, A. P., Diaz, R., Berry, C., Koenig, W., Lopez-Sendon, J., Gamra, H., Kiwan, G. S., Blondeau, L., Orfanos, A., Ibrahim, R., Grégoire, J. C., Dubé, M. P., Samuel, M., Morel, O., Lim, P., Bertrand, O. F., Kouz, S., Guertin, M. C., L'Allier, P. L. and Roubille, F. Eur Heart J 2020; 42: 4092-4099. [BibTeX]
  • A genetic model of ivabradine recapitulates results from randomized clinical trials. Legault, M. A., Sandoval, J., Provost, S., Barhdadi, A., Lemieux Perreault, L. P., Shah, S., Lumbers, R. T., de Denus, S., Tyl, B., Tardif, J. C. and Dubé, M. P. PLoS One 2020; 7: e0236193. [BibTeX]
  • High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Busque, L., Sun, M., Buscarlet, M., Ayachi, S., Feroz Zada, Y., Provost, S., Bourgoin, V., Mollica, L., Meisel, M., Hinterleitner, R., Jabri, B., Dubé, M. P. and Tardif, J. C. Blood Adv 2020; 11: 2430-2438. [BibTeX]
  • Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. de Denus, S., Leclair, G., Dubé, M. P., St-Jean, I., Zada, Y. F., Oussaïd, E., Jutras, M., Givertz, M. M., Mentz, R. J., Tang, W. H. W., Ferreira, J. P., Rouleau, J., Butler, J. and Kalogeropoulos, A. P. Eur J Heart Fail 2020; 8: 1451-1461. [BibTeX]
  • CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. Meloche, M., Khazaka, M., Kassem, I., Barhdadi, A., Dubé, M. P. and de Denus, S. Br J Clin Pharmacol 2020; 6: 1015-1033. [BibTeX]
  • Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. Tardif, J. C., Dubé, M. P., Pfeffer, M. A., Waters, D. D., Koenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., White, H. D., Heinonen, T., Black, D. M. and Guertin, M. C. Am Heart J 2020: 157-165. [BibTeX]
  • Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study. Cadby, G., Melton, P. E., McCarthy, N. S., Giles, C., Mellett, N. A., Huynh, K., Hung, J., Beilby, J., Dubé, M. P., Watts, G. F., Blangero, J., Meikle, P. J. and Moses, E. K. J Lipid Res 2020; 4: 537-545. [BibTeX]
  • Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Perreault, S., de Denus, S., White-Guay, B., Côté, R., Schnitzer, M. E., Dubé, M. P., Dorais, M. and Tardif, J. C. Pharmacotherapy 2020; 1: 40-54. [BibTeX]
  • rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B. Mouammine, A., Gravel, A., Dubuc, I., Feroz Zada, Y., Provost, S., Busseuil, D., Tardif, J. C., Dubé, M. P. and Flamand, L. J Infect Dis 2020; 6: 878-881. [BibTeX]

2019

  • Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. Tardif, J. C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M. A., Dubé, M. P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L'Allier, P. L., Guertin, M. C. and Roubille, F. N Engl J Med 2019; 26: 2497-2505. [BibTeX]
  • Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes. AlTurki, A., Marafi, M., Dawas, A., Dube, M. P., Vieira, L., Sherman, M. H., Gregoire, J., Thanassoulis, G., Tardif, J. C. and Huynh, T. Am J Cardiol 2019; 12: 1869-1875. [BibTeX]
  • That Correlates with an Increased Antibody Immune Response. Peddu, V., Dubuc, I., Gravel, A., Xie, H., Huang, M. L., Tenenbaum, D., Jerome, K. R., Tardif, J. C., Dubé, M. P., Flamand, L. and Greninger, A. L. J Virol 2019; 1. [BibTeX]
  • Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians. Wünnemann, F., Sin Lo, K., Langford-Avelar, A., Busseuil, D., Dubé, M. P., Tardif, J. C. and Lettre, G. Circ Genom Precis Med 2019; 6: e002481. [BibTeX]
  • Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Patel, R. S., Schmidt, A. F., Tragante, V., McCubrey, R. O., Holmes, M. V., Howe, L. J., Direk, K., Åkerblom, A., Leander, K., Virani, S. S., Kaminski, K. A., Muehlschlegel, J. D., Dubé, M. P., Allayee, H., Almgren, P., Alver, M., Baranova, E. V., Behlouli, H., Boeckx, B., Braund, P. S., Breitling, L. P., Delgado, G., Duarte, N. E., Dufresne, L., Eriksson, N., Foco, L., Gijsberts, C. M., Gong, Y., Hartiala, J., Heydarpour, M. et al. Circ Genom Precis Med 2019; 4: e002471. [BibTeX]
  • Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Patel, R. S., Tragante, V., Schmidt, A. F., McCubrey, R. O., Holmes, M. V., Howe, L. J., Direk, K., Åkerblom, A., Leander, K., Virani, S. S., Kaminski, K. A., Muehlschlegel, J. D., Allayee, H., Almgren, P., Alver, M., Baranova, E. V., Behloui, H., Boeckx, B., Braund, P. S., Breitling, L. P., Delgado, G., Duarte, N. E., Dubé, M. P., Dufresne, L., Eriksson, N., Foco, L., Scholz, M., Gijsberts, C. M., Glinge, C., Gong, Y. et al. Circ Genom Precis Med 2019; 4: e002470. [BibTeX]
  • Lipoprotein (a), arterial inflammation, and PCSK9 inhibition. Tardif, J. C., Rhéaume, E., Rhainds, D. and Dubé, M. P. Eur Heart J 2019; 33: 2782-2784. [BibTeX]
  • Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Justice, A. E., Karaderi, T., Highland, H. M., Young, K. L., Graff, M., Lu, Y., Turcot, V., Auer, P. L., Fine, R. S., Guo, X., Schurmann, C., Lempradl, A., Marouli, E., Mahajan, A., Winkler, T. W., Locke, A. E., Medina-Gomez, C., Esko, T., Vedantam, S., Giri, A., Lo, K. S., Alfred, T., Mudgal, P., Ng, M. C. Y., Heard-Costa, N. L., Feitosa, M. F., Manning, A. K., Willems, S. M., Sivapalaratnam, S., Abecasis, G. et al. Nat Genet 2019; 3: 452-469. [BibTeX]
  • Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort. Shahabi, P., Lamothe, F., Dumas, S., Rouleau-Mailloux, É., Feroz Zada, Y., Provost, S., Asselin, G., Mongrain, I., Valois, D., Gaulin Marion, M. J., Lemieux Perreault, L. P., Perreault, S. and Dubé, M. P. Pharmacogenomics J 2019; 2: 147-156. [BibTeX]

2018

  • Variants at the APOE /C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol. Low-Kam, C., Rhainds, D., Lo, K. S., Barhdadi, A., Boulé, M., Alem, S., Pedneault-Gagnon, V., Rhéaume, E., Dubé, M. P., Busseuil, D., Hegele, R. A., Lettre, G. and Tardif, J. C. J Am Heart Assoc 2018; 16: e009545. [BibTeX]
  • Pharmacogenetic content of commercial genome-wide genotyping arrays. Lemieux Perreault, L. P., Zaïd, N., Cameron, M., Mongrain, I. and Dubé, M. P. Pharmacogenomics 2018; 15: 1159-1167. [BibTeX]
  • Biomarkers of dementia in obstructive sleep apnea. Baril, A. A., Carrier, J., Lafrenière, A., Warby, S., Poirier, J., Osorio, R. S., Ayas, N., Dubé, M. P., Petit, D. and Gosselin, N. Sleep Med Rev 2018: 139-148. [BibTeX]
  • Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype. Pfeffer, M. A., Dubé, M. P. and Tardif, J. C. JAMA Cardiol 2018; 9: 897. [BibTeX]
  • Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. Levinsson, A., Dubé, M. P., Tardif, J. C. and de Denus, S. ESC Heart Fail 2018; 5: 745-754. [BibTeX]
  • . Buscarlet, M., Provost, S., Zada, Y. F., Bourgoin, V., Mollica, L., Dubé, M. P. and Busque, L. Blood 2018; 3: 277-280. [BibTeX]
  • Pharmacogenomics of blood lipid regulation. Legault, M. A., Tardif, J. C. and Dubé, M. P. Pharmacogenomics 2018; 7: 651-665. [BibTeX]
  • A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. de Denus, S., Dubé, M. P., Fouodjio, R., Huynh, T., LeBlanc, M. H., Lepage, S., Sheppard, R., Giannetti, N., Lavoie, J., Mansour, A., Provost, S., Normand, V., Mongrain, I., Langlois, M., O'Meara, E., Ducharme, A., Racine, N., Guertin, M. C., Turgeon, J., Phillips, M. S., Rouleau, J. L., Tardif, J. C. and White, M. Pharmacogenomics 2018; 7: 599-612. [BibTeX]
  • ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein). Rautureau, Y., Deschambault, V., Higgins, M. È., Rivas, D., Mecteau, M., Geoffroy, P., Miquel, G., Uy, K., Sanchez, R., Lavoie, V., Brand, G., Nault, A., Williams, P. M., Suarez, M. L., Merlet, N., Lapointe, L., Duquette, N., Gillis, M. A., Samami, S., Mayer, G., Pouliot, P., Raignault, A., Maafi, F., Brodeur, M. R., Levesque, S., Guertin, M. C., Dubé, M. P., Thorin, É., Rhainds, D., Rhéaume, É. et al. Circulation 2018; 16: 1677-1692. [BibTeX]
  • A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Mitchell, D., Guertin, J. R., Dubois, A., Dubé, M. P., Tardif, J. C., Iliza, A. C., Fanton-Aita, F., Matteau, A. and LeLorier, J. Mol Diagn Ther 2018; 2: 241-254. [BibTeX]
  • Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Perreault, S., Shahabi, P., Côté, R., Dumas, S., Rouleau-Mailloux, É., Feroz Zada, Y., Provost, S., Mongrain, I., Dorais, M., Huynh, T., Kouz, S., Diaz, A., Blostein, M., de Denus, S., Turgeon, J., Ginsberg, J., Lelorier, J., Lalonde, L., Busque, L., Kassis, J., Talajic, M., Tardif, J. C. and Dubé, M. P. Clin Cardiol 2018; 5: 576-585. [BibTeX]
  • Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Turcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., Guo, X., Hendricks, A. E., Karaderi, T., Lempradl, A., Locke, A. E., Mahajan, A., Marouli, E., Sivapalaratnam, S., Young, K. L., Alfred, T., Feitosa, M. F., Masca, N. G. D., Manning, A. K., Medina-Gomez, C., Mudgal, P., Ng, M. C. Y., Reiner, A. P., Vedantam, S., Willems, S. M., Winkler, T. W. et al. Nat Genet 2018; 1: 26-41. [BibTeX]
  • Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent. Villanueva, A., Biswas, P., Kishaba, K., Suk, J., Tadimeti, K., Raghavendra, P. B., Nadeau, K., Lamontagne, B., Busque, L., Geoffroy, S., Mongrain, I., Asselin, G., Provost, S., Dubé, M. P., Nudleman, E. and Ayyagari, R. Ophthalmic Genet 2018; 1: 73-79. [BibTeX]
  • CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. de Denus, S., Rouleau, J. L., Mann, D. L., Huggins, G. S., Pereira, N. L., Shah, S. H., Cappola, T. P., Fouodjio, R., Mongrain, I. and Dubé, M. P. Pharmacogenomics J 2018; 2: 232-237. [BibTeX]

2017

  • 300,000 individuals. Liu, D. J., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., Mahajan, A., Saleheen, D., Emdin, C., Alam, D., Alves, A. C., Amouyel, P., Di Angelantonio, E., Arveiler, D., Assimes, T. L., Auer, P. L., Baber, U., Ballantyne, C. M., Bang, L. E., Benn, M., Bis, J. C., Boehnke, M., Boerwinkle, E., Bork-Jensen, J., Bottinger, E. P., Brandslund, I., Brown, M., Busonero, F., Caulfield, M. J., Chambers, J. C., Chasman, D. I. et al. Nat Genet 2017; 12: 1758-1766. [BibTeX]
  • Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Messas, N., Dubé, M. P. and Tardif, J. C. Curr Atheroscler Rep 2017; 11: 43. [BibTeX]
  • ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. Trigueros-Motos, L., van Capelleveen, J. C., Torta, F., Castaño, D., Zhang, L. H., Chai, E. C., Kang, M., Dimova, L. G., Schimmel, A. W. M., Tietjen, I., Radomski, C., Tan, L. J., Thiam, C. H., Narayanaswamy, P., Wu, D. H., Dorninger, F., Yakala, G. K., Barhdadi, A., Angeli, V., Dubé, M. P., Berger, J., Dallinga-Thie, G. M., Tietge, U. J. F., Wenk, M. R., Hayden, M. R., Hovingh, G. K. and Singaraja, R. R. Arterioscler Thromb Vasc Biol 2017; 11: 2147-2155. [BibTeX]
  • Polygenic determinants in extremes of high-density lipoprotein cholesterol. Dron, J. S., Wang, J., Low-Kam, C., Khetarpal, S. A., Robinson, J. F., McIntyre, A. D., Ban, M. R., Cao, H., Rhainds, D., Dubé, M. P., Rader, D. J., Lettre, G., Tardif, J. C. and Hegele, R. A. J Lipid Res 2017; 11: 2162-2170. [BibTeX]
  • CKing Precision in the Interpretation of Diagnostic Biomarkers. de Denus, S., Tardif, J. C. and Dubé, M. P. Circ Cardiovasc Genet 2017; 4. [BibTeX]
  • dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Buscarlet, M., Provost, S., Zada, Y. F., Barhdadi, A., Bourgoin, V., Lépine, G., Mollica, L., Szuber, N., Dubé, M. P. and Busque, L. Blood 2017; 6: 753-762. [BibTeX]
  • Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies. Kuate Defo, B., Mbanya, J. C., Tardif, J. C., Ekundayo, O., Perreault, S., Potvin, L., Cote, R., Kengne, A. P., Choukem, S. P., Assah, F., Kingue, S., Richard, L., Pongou, R., Frohlich, K., Saji, J., Fournier, P., Sobngwi, E., Ridde, V., Dubé, M. P., De Denus, S., Mbacham, W., Lafrance, J. P., Nsagha, D. S., Mampuya, W., Dzudie, A., Cloutier, L., Zarowsky, C., Tanya, A., Ndom, P., Hatem, M. et al. JMIR Res Protoc 2017; 5: e102. [BibTeX]
  • Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve. Yang, B., Zhou, W., Jiao, J., Nielsen, J. B., Mathis, M. R., Heydarpour, M., Lettre, G., Folkersen, L., Prakash, S., Schurmann, C., Fritsche, L., Farnum, G. A., Lin, M., Othman, M., Hornsby, W., Driscoll, A., Levasseur, A., Thomas, M., Farhat, L., Dubé, M. P., Isselbacher, E. M., Franco-Cereceda, A., Guo, D. C., Bottinger, E. P., Deeb, G. M., Booher, A., Kheterpal, S., Chen, Y. E., Kang, H. M., Kitzman, J. et al. Nat Commun 2017: 15481. [BibTeX]
  • Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol. Rivollier, F., Chaumette, B., Bendjemaa, N., Chayet, M., Millet, B., Jaafari, N., Barhdadi, A., Lemieux Perreault, L. P., Provost, S., Dubé, M. P., Gaillard, R., Krebs, M. O. and Kebir, O. PLoS One 2017; 4: e0174783. [BibTeX]
  • Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. Webb, T. R., Erdmann, J., Stirrups, K. E., Stitziel, N. O., Masca, N. G., Jansen, H., Kanoni, S., Nelson, C. P., Ferrario, P. G., König, I. R., Eicher, J. D., Johnson, A. D., Hamby, S. E., Betsholtz, C., Ruusalepp, A., Franzén, O., Schadt, E. E., Björkegren, J. L., Weeke, P. E., Auer, P. L., Schick, U. M., Lu, Y., Zhang, H., Dube, M. P., Goel, A., Farrall, M., Peloso, G. M., Won, H. H., Do, R., van Iperen, E. et al. J Am Coll Cardiol 2017; 7: 823-836. [BibTeX]
  • CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. Tardif, J. C., Rhainds, D., Rhéaume, E. and Dubé, M. P. Arterioscler Thromb Vasc Biol 2017; 3: 396-400. [BibTeX]
  • Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Perreault, S., de Denus, S., White, M., White-Guay, B., Bouvier, M., Dorais, M., Dubé, M. P., Rouleau, J. L., Tardif, J. C., Jenna, S., Haibe-Kains, B., Leduc, R. and Deblois, D. Pharmacoepidemiol Drug Saf 2017; 1: 81-90. [BibTeX]

2016

  • Pharmacogenomic approaches to lipid-regulating trials. Bertrand, M. J., Dubé, M. P. and Tardif, J. C. Curr Opin Lipidol 2016; 6: 557-562. [BibTeX]
  • Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Wang, J., Dron, J. S., Ban, M. R., Robinson, J. F., McIntyre, A. D., Alazzam, M., Zhao, P. J., Dilliott, A. A., Cao, H., Huff, M. W., Rhainds, D., Low-Kam, C., Dubé, M. P., Lettre, G., Tardif, J. C. and Hegele, R. A. Arterioscler Thromb Vasc Biol 2016; 12: 2439-2445. [BibTeX]
  • Paternal Age Explains a Major Portion of De Novo Germline Mutation Rate Variability in Healthy Individuals. Girard, S. L., Bourassa, C. V., Lemieux Perreault, L. P., Legault, M. A., Barhdadi, A., Ambalavanan, A., Brendgen, M., Vitaro, F., Noreau, A., Dionne, G., Tremblay, R. E., Dion, P. A., Boivin, M., Dubé, M. P. and Rouleau, G. A. PLoS One 2016; 10: e0164212. [BibTeX]
  • A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine. Iliza, A. C., Matteau, A., Guertin, J. R., Mitchell, D., Fanton-Aita, F., Dubois, A., Dubé, M. P., Tardif, J. C. and LeLorier, J. Pharmacogenomics 2016; 15: 1693-1706. [BibTeX]
  • Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population. Fanton-Aita, F., Matteau, A., Iliza, A. C., Mitchell, D., Guertin, J. R., Dubois, A., Dubé, M. P., Tardif, J. C. and LeLorier, J. Curr Med Res Opin 2016; 12: 1955-1958. [BibTeX]
  • Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Postmus, I., Warren, H. R., Trompet, S., Arsenault, B. J., Avery, C. L., Bis, J. C., Chasman, D. I., de Keyser, C. E., Deshmukh, H. A., Evans, D. S., Feng, Q., Li, X., Smit, R. A., Smith, A. V., Sun, F., Taylor, K. D., Arnold, A. M., Barnes, M. R., Barratt, B. J., Betteridge, J., Boekholdt, S. M., Boerwinkle, E., Buckley, B. M., Chen, Y. I., de Craen, A. J., Cummings, S. R., Denny, J. C., Dubé, M. P., Durrington, P. N., Eiriksdottir, G. et al. J Med Genet 2016; 12: 835-845. [BibTeX]
  • genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools. Lemieux Perreault, L. P., Legault, M. A., Asselin, G. and Dubé, M. P. Bioinformatics 2016; 23: 3661-3663. [BibTeX]
  • Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Tardif, J. C., Rhainds, D., Brodeur, M., Feroz Zada, Y., Fouodjio, R., Provost, S., Boulé, M., Alem, S., Grégoire, J. C., L'Allier, P. L., Ibrahim, R., Guertin, M. C., Mongrain, I., Olsson, A. G., Schwartz, G. G., Rhéaume, E. and Dubé, M. P. Circ Cardiovasc Genet 2016; 4: 340-348. [BibTeX]
  • Whole-genome sequencing in French Canadians from Quebec. Low-Kam, C., Rhainds, D., Lo, K. S., Provost, S., Mongrain, I., Dubois, A., Perreault, S., Robinson, J. F., Hegele, R. A., Dubé, M. P., Tardif, J. C. and Lettre, G. Hum Genet 2016; 11: 1213-1221. [BibTeX]
  • DNA methylation signature of human fetal alcohol spectrum disorder. Portales-Casamar, E., Lussier, A. A., Jones, M. J., MacIsaac, J. L., Edgar, R. D., Mah, S. M., Barhdadi, A., Provost, S., Lemieux-Perreault, L. P., Cynader, M. S., Chudley, A. E., Dubé, M. P., Reynolds, J. N., Pavlidis, P. and Kobor, M. S. Epigenetics Chromatin 2016: 25. [BibTeX]
  • Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. Eicher, J. D., Chami, N., Kacprowski, T., Nomura, A., Chen, M. H., Yanek, L. R., Tajuddin, S. M., Schick, U. M., Slater, A. J., Pankratz, N., Polfus, L., Schurmann, C., Giri, A., Brody, J. A., Lange, L. A., Manichaikul, A., Hill, W. D., Pazoki, R., Elliot, P., Evangelou, E., Tzoulaki, I., Gao, H., Vergnaud, A. C., Mathias, R. A., Becker, D. M., Becker, L. C., Burt, A., Crosslin, D. R., Lyytikäinen, L. P., Nikus, K. et al. Am J Hum Genet 2016; 1: 40-55. [BibTeX]
  • Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. Chami, N., Chen, M. H., Slater, A. J., Eicher, J. D., Evangelou, E., Tajuddin, S. M., Love-Gregory, L., Kacprowski, T., Schick, U. M., Nomura, A., Giri, A., Lessard, S., Brody, J. A., Schurmann, C., Pankratz, N., Yanek, L. R., Manichaikul, A., Pazoki, R., Mihailov, E., Hill, W. D., Raffield, L. M., Burt, A., Bartz, T. M., Becker, D. M., Becker, L. C., Boerwinkle, E., Bork-Jensen, J., Bottinger, E. P., O'Donoghue, M. L., Crosslin, D. R. et al. Am J Hum Genet 2016; 1: 8-21. [BibTeX]
  • Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users. Dumas, S., Rouleau-Mailloux, E., Bouchama, N., Lahcene, H., Talajic, M., Tardif, J. C., Gaulin, M. J., Provost, S., Dubé, M. P. and Perreault, S. J Manag Care Spec Pharm 2016; 6: 676-684. [BibTeX]
  • An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Shahabi, P., Scheinfeldt, L. B., Lynch, D. E., Schmidlen, T. J., Perreault, S., Keller, M. A., Kasper, R., Wawak, L., Jarvis, J. P., Gerry, N. P., Gordon, E. S., Christman, M. F., Dubé, M. P. and Gharani, N. Thromb Haemost 2016; 2: 337-348. [BibTeX]
  • Methylomic changes during conversion to psychosis. Kebir, O., Chaumette, B., Rivollier, F., Miozzo, F., Lemieux Perreault, L. P., Barhdadi, A., Provost, S., Plaze, M., Bourgin, J., Gaillard, R., Mezger, V., Dubé, M. P., Krebs, M. O., Mam-Lam-Fook, C., Alexandre, C., Magadu, E., Martinez, G., Kazes, M., Chayet, M., Gay, O. and Prost, Z. Mol Psychiatry 2017; 4: 512-518. [BibTeX]
  • Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. Stitziel, N. O., Stirrups, K. E., Masca, N. G., Erdmann, J., Ferrario, P. G., König, I. R., Weeke, P. E., Webb, T. R., Auer, P. L., Schick, U. M., Lu, Y., Zhang, H., Dube, M. P., Goel, A., Farrall, M., Peloso, G. M., Won, H. H., Do, R., van Iperen, E., Kanoni, S., Kruppa, J., Mahajan, A., Scott, R. A., Willenberg, C., Braund, P. S., van Capelleveen, J. C., Doney, A. S., Donnelly, L. A., Asselta, R., Merlini, P. A. et al. N Engl J Med 2016; 12: 1134-1144. [BibTeX]
  • A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. de Denus, S., Rouleau, J. L., Mann, D. L., Huggins, G. S., Cappola, T. P., Shah, S. H., Keleti, J., Zada, Y. F., Provost, S., Bardhadi, A., Phillips, M. S., Normand, V., Mongrain, I. and Dubé, M. P. Pharmacogenomics J 2017; 2: 192-200. [BibTeX]
  • Avoidance of Vitamin K-Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes. Leblanc, C., Dubé, M. P., Presse, N., Dumas, S., Nguyen, M., Rouleau-Mailloux, É., Perreault, S. and Ferland, G. J Acad Nutr Diet 2016; 6: 1000-1007. [BibTeX]
  • Testing the role of predicted gene knockouts in human anthropometric trait variation. Lessard, S., Manning, A. K., Low-Kam, C., Auer, P. L., Giri, A., Graff, M., Schurmann, C., Yaghootkar, H., Luan, J., Esko, T., Karaderi, T., Bottinger, E. P., Lu, Y., Carlson, C., Caulfield, M., Dubé, M. P., Jackson, R. D., Kooperberg, C., McKnight, B., Mongrain, I., Peters, U., Reiner, A. P., Rhainds, D., Sotoodehnia, N., Hirschhorn, J. N., Scott, R. A., Munroe, P. B., Frayling, T. M., Loos, R. J., North, K. E. et al. Hum Mol Genet 2016; 10: 2082-2092. [BibTeX]
  • Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Dubé, M. P., de Denus, S. and Tardif, J. C. Cardiovasc Drugs Ther 2016; 1: 59-64. [BibTeX]
  • Impact of regular physical activity on weekly warfarin dose requirement. Rouleau-Mailloux, É., Shahabi, P., Dumas, S., Feroz Zada, Y., Provost, S., Hu, J., Nguyen, J., Bouchama, N., Mongrain, I., Talajic, M., Tardif, J. C., Perreault, S. and Dubé, M. P. J Thromb Thrombolysis 2016; 2: 328-335. [BibTeX]

2015

  • Resting heart rate as a predictor of aortic valve stenosis progression. de Oliveira Moraes, A. B., Stähli, B. E., Arsenault, B. J., Busseuil, D., Merlet, N., Gebhard, C., Fortier, A., Rhainds, D., Dubé, M. P., Guertin, M. C., Asgar, A., Rhéaume, E. and Tardif, J. C. Int J Cardiol 2016: 149-151. [BibTeX]
  • Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease. Guauque-Olarte, S., Messika-Zeitoun, D., Droit, A., Lamontagne, M., Tremblay-Marchand, J., Lavoie-Charland, E., Gaudreault, N., Arsenault, B. J., Dubé, M. P., Tardif, J. C., Body, S. C., Seidman, J. G., Boileau, C., Mathieu, P., Pibarot, P. and Bossé, Y. Circ Cardiovasc Genet 2015; 6: 812-822. [BibTeX]
  • Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use. de Denus, S., Dubé, M. P. and Tardif, J. C. Expert Opin Pharmacother 2015; 17: 2549-2552. [BibTeX]
  • Mutation burden of rare variants in schizophrenia candidate genes. Girard, S. L., Dion, P. A., Bourassa, C. V., Geoffroy, S., Lachance-Touchette, P., Barhdadi, A., Langlois, M., Joober, R., Krebs, M. O., Dubé, M. P. and Rouleau, G. A. PLoS One 2015; 6: e0128988. [BibTeX]
  • Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. Jarjour, S., Barrette, M., Normand, V., Rouleau, J. L., Dubé, M. P. and de Denus, S. Pharmacogenomics 2015; 7: 755-767. [BibTeX]
  • Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. Shahabi, P. and Dubé, M. P. Int J Cardiol 2015: 772-795. [BibTeX]
  • Comparison of sequencing based CNV discovery methods using monozygotic twin quartets. Legault, M. A., Girard, S., Lemieux Perreault, L. P., Rouleau, G. A. and Dubé, M. P. PLoS One 2015; 3: e0122287. [BibTeX]
  • Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Tardif, J. C., Rhéaume, E., Lemieux Perreault, L. P., Grégoire, J. C., Feroz Zada, Y., Asselin, G., Provost, S., Barhdadi, A., Rhainds, D., L'Allier, P. L., Ibrahim, R., Upmanyu, R., Niesor, E. J., Benghozi, R., Suchankova, G., Laghrissi-Thode, F., Guertin, M. C., Olsson, A. G., Mongrain, I., Schwartz, G. G. and Dubé, M. P. Circ Cardiovasc Genet 2015; 2: 372-382. [BibTeX]

2014

  • Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Postmus, I., Trompet, S., Deshmukh, H. A., Barnes, M. R., Li, X., Warren, H. R., Chasman, D. I., Zhou, K., Arsenault, B. J., Donnelly, L. A., Wiggins, K. L., Avery, C. L., Griffin, P., Feng, Q., Taylor, K. D., Li, G., Evans, D. S., Smith, A. V., de Keyser, C. E., Johnson, A. D., de Craen, A. J., Stott, D. J., Buckley, B. M., Ford, I., Westendorp, R. G., Slagboom, P. E., Sattar, N., Munroe, P. B., Sever, P., Poulter, N. et al. Nat Commun 2014: 5068. [BibTeX]
  • CKM and LILRB5 are associated with serum levels of creatine kinase. Dubé, M. P., Zetler, R., Barhdadi, A., Brown, A. M., Mongrain, I., Normand, V., Laplante, N., Asselin, G., Zada, Y. F., Provost, S., Bergeron, J., Kouz, S., Dufour, R., Diaz, A., de Denus, S., Turgeon, J., Rhéaume, E., Phillips, M. S. and Tardif, J. C. Circ Cardiovasc Genet 2014; 6: 880-886. [BibTeX]
  • Genetic markers of cisplatin-induced hearing loss in children. Carleton, B. C., Ross, C. J., Pussegoda, K., Bhavsar, A. P., Visscher, H., Lee, J. W., Brooks, B., Rassekh, S. R., Dubé, M. P. and Hayden, M. R. Clin Pharmacol Ther 2014; 3: 296-298. [BibTeX]
  • Development of a broad-based ADME panel for use in pharmacogenomic studies. Brown, A. M., Renaud, Y., Ross, C., Hansen, M., Mongrain, I., Valois, D., Carleton, B. C., Hayden, M. R., Dubé, M. P., Tardif, J. C. and Phillips, M. S. Pharmacogenomics 2014; 9: 1185-1195. [BibTeX]
  • Modifiers of (CAG)(n) instability in Machado-Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes. Martins, S., Pearson, C. E., Coutinho, P., Provost, S., Amorim, A., Dubé, M. P., Sequeiros, J. and Rouleau, G. A. Hum Genet 2014; 10: 1311-1318. [BibTeX]
  • Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. Auer, P. L., Teumer, A., Schick, U., O'Shaughnessy, A., Lo, K. S., Chami, N., Carlson, C., de Denus, S., Dubé, M. P., Haessler, J., Jackson, R. D., Kooperberg, C., Perreault, L. P., Nauck, M., Peters, U., Rioux, J. D., Schmidt, F., Turcot, V., Völker, U., Völzke, H., Greinacher, A., Hsu, L., Tardif, J. C., Diaz, G. A., Reiner, A. P. and Lettre, G. Nat Genet 2014; 6: 629-634. [BibTeX]
  • Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Arsenault, B. J., Boekholdt, S. M., Dubé, M. P., Rhéaume, E., Wareham, N. J., Khaw, K. T., Sandhu, M. S. and Tardif, J. C. Circ Cardiovasc Genet 2014; 3: 304-310. [BibTeX]
  • Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer's Disease. El Kadmiri, N., Zaid, N., Zaid, Y., Tadevosyan, A., Hachem, A., Dubé, M. P., Hamzi, K., El Moutawakil, B., Slassi, I. and Nadifi, S. Neuroscience 2014: 215-222. [BibTeX]
  • Novel mutations in the amyloid precursor protein gene within Moroccan patients with Alzheimer's disease. El Kadmiri, N., Zaid, N., Hachem, A., Zaid, Y., Dubé, M. P., Hamzi, K., El Moutawakil, B., Slassi, I. and Nadifi, S. J Mol Neurosci 2014; 2: 189-195. [BibTeX]
  • Comparison of genotype clustering tools with rare variants. Perreault, L. P., Legault, M. A., Barhdadi, A., Provost, S., Normand, V., Tardif, J. C. and Dubé, M. P. BMC Bioinformatics 2014: 52. [BibTeX]
  • Cuckoo search epistasis: a new method for exploring significant genetic interactions. Aflakparast, M., Salimi, H., Gerami, A., Dubé, M. P., Visweswaran, S. and Masoudi-Nejad, A. Heredity (Edinb) 2014; 6: 666-674. [BibTeX]
  • Validation of patient-reported warfarin dose in a prospective incident cohort study. Dumas, S., Rouleau-Mailloux, E., Barhdadi, A., Talajic, M., Tardif, J. C., Dubé, M. P. and Perreault, S. Pharmacoepidemiol Drug Saf 2014; 3: 285-289. [BibTeX]
  • Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans. Arsenault, B. J., Dubé, M. P., Brodeur, M. R., de Oliveira Moraes, A. B., Lavoie, V., Kernaleguen, A. E., Guauque-Olarte, S., Mathieu, P., Pibarot, P., Messika-Zeitoun, D., Bossé, Y., Rhainds, D., Rhéaume, E. and Tardif, J. C. Arterioscler Thromb Vasc Biol 2014; 2: 457-462. [BibTeX]
  • Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Carleton, B. C., Ross, C. J., Bhavsar, A. P., Amstutz, U., Pussegoda, K., Visscher, H., Lee, J. W., Brooks, B., Rassekh, S. R., Dubé, M. P. and Hayden, M. R. Clin Pharmacol Ther 2014; 3: 253. [BibTeX]
  • Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Aminkeng, F., Ross, C. J., Rassekh, S. R., Brunham, L. R., Sistonen, J., Dube, M. P., Ibrahim, M., Nyambo, T. B., Omar, S. A., Froment, A., Bodo, J. M., Tishkoff, S., Carleton, B. C., Hayden, M. R., Hayden, M., Carleton, B., Ross, C., MacLeod, S., Wasserman, W., Mitton, C., Smith, A., Hildebrand, C., Castro Pastrana, L., Ghannadan, R., Rassekh, R., Lim, J., Miao, F., Visscher, H., Pussegoda, K., Aminkeng, F. et al. Pharmacogenomics J 2014; 2: 160-170. [BibTeX]

2013

  • pyGenClean: efficient tool for genetic data clean up before association testing. Lemieux Perreault, L. P., Provost, S., Legault, M. A., Barhdadi, A. and Dubé, M. P. Bioinformatics 2013; 13: 1704-1705. [BibTeX]
  • Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Pussegoda, K., Ross, C. J., Visscher, H., Yazdanpanah, M., Brooks, B., Rassekh, S. R., Zada, Y. F., Dubé, M. P., Carleton, B. C., Hayden, M. R., Hayden, M., Carleton, B., Ross, C., MacLeod, S., Brooks, B., Smith, A., Hildebrand, C., Ghannadan, R., Rassekh, R., Miao, F., Visscher, H., Pussegoda, K., Higginson, M., Yazdanpanah, M., Nijssen-Jordan, C., Johnson, D., Verbeek, L., Kaczowka, R., Stevenson, P., Hurton, A. et al. Clin Pharmacol Ther 2013; 2: 243-251. [BibTeX]
  • Institutional profile: the Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute. Dubé, M. P. and Tardif, J. C. Pharmacogenomics 2013; 2: 131-136. [BibTeX]
  • The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Singaraja, R. R., Sivapalaratnam, S., Hovingh, K., Dubé, M. P., Castro-Perez, J., Collins, H. L., Adelman, S. J., Riwanto, M., Manz, J., Hubbard, B., Tietjen, I., Wong, K., Mitnaul, L. J., van Heek, M., Lin, L., Roddy, T. A., McEwen, J., Dallinge-Thie, G., van Vark-van der Zee, L., Verwoert, G., Winther, M., van Duijn, C., Hofman, A., Trip, M. D., Marais, A. D., Asztalos, B., Landmesser, U., Sijbrands, E., Kastelein, J. J. and Hayden, M. R. Circ Cardiovasc Genet 2013; 1: 54-62. [BibTeX]
  • Risk of congenital heart defects is influenced by genetic variation in folate metabolism. Christensen, K. E., Zada, Y. F., Rohlicek, C. V., Andelfinger, G. U., Michaud, J. L., Bigras, J. L., Richter, A., Dubé, M. P. and Rozen, R. Cardiol Young 2013; 1: 89-98. [BibTeX]

2012

  • Rare copy number variants contribute to congenital left-sided heart disease. Hitz, M. P., Lemieux-Perreault, L. P., Marshall, C., Feroz-Zada, Y., Davies, R., Yang, S. W., Lionel, A. C., D'Amours, G., Lemyre, E., Cullum, R., Bigras, J. L., Thibeault, M., Chetaille, P., Montpetit, A., Khairy, P., Overduin, B., Klaassen, S., Hoodless, P., Awadalla, P., Hussin, J., Idaghdour, Y., Nemer, M., Stewart, A. F., Boerkoel, C., Scherer, S. W., Richter, A., Dubé, M. P. and Andelfinger, G. PLoS Genet 2012; 9: e1002903. [BibTeX]
  • Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol. Tietjen, I., Hovingh, G. K., Singaraja, R. R., Radomski, C., Barhdadi, A., McEwen, J., Chan, E., Mattice, M., Legendre, A., Franchini, P. L., Dubé, M. P., Kastelein, J. J. and Hayden, M. R. PLoS One 2012; 8: e37437. [BibTeX]
  • Pooled DNA resequencing of 68 myocardial infarction candidate genes in French canadians. Beaudoin, M., Lo, K. S., N'Diaye, A., Rivas, M. A., Dubé, M. P., Laplante, N., Phillips, M. S., Rioux, J. D., Tardif, J. C. and Lettre, G. Circ Cardiovasc Genet 2012; 5: 547-554. [BibTeX]
  • Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice. Wiltshire, S. A., Diez, E., Miao, Q., Dubé, M. P., Gagné, M., Paquette, O., Lafrenière, R. G., Ndao, M., Castellani, L. W., Skamene, E., Vidal, S. M. and Fortin, A. Physiol Genomics 2012; 17: 843-852. [BibTeX]
  • Tacrolimus-induced nephrotoxicity and genetic variability: a review. Gijsen, V. M., Madadi, P., Dube, M. P., Hesselink, D. A., Koren, G. and de Wildt, S. N. Ann Transplant 2012; 2: 111-121. [BibTeX]
  • A novel PLP1 mutation further expands the clinical heterogeneity at the locus. Hand, C. K., Bernard, G., Dubé, M. P., Shevell, M. I. and Rouleau, G. A. Can J Neurol Sci 2012; 2: 220-224. [BibTeX]
  • PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients. Lachance, K., Barhdadi, A., Mongrain, I., Normand, V., Zakrzewski, M., Leblanc, M. H., Racine, N., Carrier, M., Ducharme, A., Turgeon, J., Dubé, M. P., Phillips, M. S., White, M. and de Denus, S. Pharmacogenet Genomics 2012; 5: 336-343. [BibTeX]
  • Validation of warfarin pharmacogenetic algorithms in clinical practice. Marin-Leblanc, M., Perreault, S., Bahroun, I., Lapointe, M., Mongrain, I., Provost, S., Turgeon, J., Talajic, M., Brugada, R., Phillips, M., Tardif, J. C. and Dubé, M. P. Pharmacogenomics 2012; 1: 21-29. [BibTeX]
  • Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Visscher, H., Ross, C. J., Rassekh, S. R., Barhdadi, A., Dubé, M. P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., van der Pal, H. J., Brown, A. M., Rogers, P. C., Phillips, M. S., Rieder, M. J., Carleton, B. C., Hayden, M. R., Visscher, H., Ross, C. J., Rassekh, S., Dube, M. P., Sandor, G. S., Rogers, P. C., Phillips, M. S., Rieder, M. J., Carleton, B. C., Hayden, M. R., Rassekh, S., Caron, H. N., van Dalen, E. C. et al. J Clin Oncol 2012; 13: 1422-1428. [BibTeX]

2011

  • Mutations in a novel serine protease PRSS56 in families with nanophthalmos. Orr, A., Dubé, M. P., Zenteno, J. C., Jiang, H., Asselin, G., Evans, S. C., Caqueret, A., Lakosha, H., Letourneau, L., Marcadier, J., Matsuoka, M., Macgillivray, C., Nightingale, M., Papillon-Cavanagh, S., Perry, S., Provost, S., Ludman, M., Guernsey, D. L. and Samuels, M. E. Mol Vis 2011: 1850-1861. [BibTeX]
  • Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec. Dubé, M. P., Bigras, J. L., Thibeault, M., Bureau, N., Chetaille, P., Richter, A., Mercier, J., Bellavance, M., Rohlicek, C., Rozen, R., Nemer, M., Khairy, P., Gendron, R. and Andelfinger, G. Cardiol Young 2011; 6: 654-664. [BibTeX]
  • Fetal alcohol spectrum disorders: gene-environment interactions, predictive biomarkers, and the relationship between structural alterations in the brain and functional outcomes. Reynolds, J. N., Weinberg, J., Clarren, S., Beaulieu, C., Rasmussen, C., Kobor, M., Dube, M. P. and Goldowitz, D. Semin Pediatr Neurol 2011; 1: 49-55. [BibTeX]
  • Familial ventricular aneurysms and septal defects map to chromosome 10p15. Tremblay, N., Yang, S. W., Hitz, M. P., Asselin, G., Ginns, J., Riopel, K., Gendron, R., Montpetit, A., Duhig, E., Dubé, M. P., Radford, D. and Andelfinger, G. Eur Heart J 2011; 5: 568-573. [BibTeX]
  • Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. de Denus, S., Zakrzewski, M., Barhdadi, A., Leblanc, M. H., Racine, N., Bélanger, F., Carrier, M., Ducharme, A., Dubé, M. P., Turgeon, J. and White, M. J Heart Lung Transplant 2011; 3: 326-331. [BibTeX]

2010

  • A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Lafrenière, R. G., Cader, M. Z., Poulin, J. F., Andres-Enguix, I., Simoneau, M., Gupta, N., Boisvert, K., Lafrenière, F., McLaughlan, S., Dubé, M. P., Marcinkiewicz, M. M., Ramagopalan, S., Ansorge, O., Brais, B., Sequeiros, J., Pereira-Monteiro, J. M., Griffiths, L. R., Tucker, S. J., Ebers, G. and Rouleau, G. A. Nat Med 2010; 10: 1157-1160. [BibTeX]
  • Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Awadalla, P., Gauthier, J., Myers, R. A., Casals, F., Hamdan, F. F., Griffing, A. R., Côté, M., Henrion, E., Spiegelman, D., Tarabeux, J., Piton, A., Yang, Y., Boyko, A., Bustamante, C., Xiong, L., Rapoport, J. L., Addington, A. M., DeLisi, J. L., Krebs, M. O., Joober, R., Millet, B., Fombonne, E., Mottron, L., Zilversmit, M., Keebler, J., Daoud, H., Marineau, C., Roy-Gagnon, M. H., Dubé, M. P., Eyre-Walker, A. et al. Am J Hum Genet 2010; 3: 316-324. [BibTeX]
  • Positional cloning of a quantitative trait locus contributing to pain sensitivity: possible mediation by Tyrp1. Fortin, A., Diez, E., Ritchie, J., Sotocinal, S. G., Dube, M. P., Gagne, M., Paquette, O., Skamene, E. and Mogil, J. S. Genes Brain Behav 2010; 8: 856-867. [BibTeX]
  • Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates are... de Denus, S. and Dubé, M. P. J Hypertens 2010; 4: 668-670. [BibTeX]
  • Family study of restless legs syndrome in Quebec, Canada: clinical characterization of 671 familial cases. Xiong, L., Montplaisir, J., Desautels, A., Barhdadi, A., Turecki, G., Levchenko, A., Thibodeau, P., Dubé, M. P., Gaspar, C. and Rouleau, G. A. Arch Neurol 2010; 5: 617-622. [BibTeX]
  • Partitioning of copy-number genotypes in pedigrees. Perreault, L. P., Andelfinger, G. U., Asselin, G. and Dubé, M. P. BMC Bioinformatics 2010: 226. [BibTeX]
  • Mutations in DCC cause congenital mirror movements. Srour, M., Rivière, J. B., Pham, J. M., Dubé, M. P., Girard, S., Morin, S., Dion, P. A., Asselin, G., Rochefort, D., Hince, P., Diab, S., Sharafaddinzadeh, N., Chouinard, S., Théoret, H., Charron, F. and Rouleau, G. A. Science 2010; 5978: 592. [BibTeX]
  • De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Gauthier, J., Champagne, N., Lafrenière, R. G., Xiong, L., Spiegelman, D., Brustein, E., Lapointe, M., Peng, H., Côté, M., Noreau, A., Hamdan, F. F., Addington, A. M., Rapoport, J. L., Delisi, L. E., Krebs, M. O., Joober, R., Fathalli, F., Mouaffak, F., Haghighi, A. P., Néri, C., Dubé, M. P., Samuels, M. E., Marineau, C., Stone, E. A., Awadalla, P., Barker, P. A., Carbonetto, S., Drapeau, P., Rouleau, G. A., Daignault, K. et al. Proc Natl Acad Sci U S A 2010; 17: 7863-7868. [BibTeX]
  • Testing for gene-gene interaction with AMMI models. Barhdadi, A. and Dubé, M. P. Stat Appl Genet Mol Biol 2010: Article 2. [BibTeX]
  • Genome-wide TDT analysis in French-Canadian families with Tourette syndrome. Rivière, J. B., St-Onge, J., Gaspar, C., Diab, S., Dion, Y., Lespérance, P., Tellier, G., Richer, F., Chouinard, S., Dubé, M. P., Rouleau, G. A., Charest, M., Chau, V., Desbeaumes, V., Dion, M. H., Duplessis, M., Girard, C., Handanos, D., Jodoin, N., Assouad, D. J., Lemay, M., Ng, A., Srour, M., Thibault, M., Tremblay, I. and Vézina, M. Can J Neurol Sci 2010; 1: 110-112. [BibTeX]
  • Genetics of bronchopulmonary dysplasia in the age of genomics. Lavoie, P. M. and Dubé, M. P. Curr Opin Pediatr 2010; 2: 134-138. [BibTeX]
  • Novel mutations in the sacsin gene in ataxia patients from Maritime Canada. Guernsey, D. L., Dubé, M. P., Jiang, H., Asselin, G., Blowers, S., Evans, S., Ferguson, M., Macgillivray, C., Matsuoka, M., Nightingale, M., Rideout, A., Delatycki, M., Orr, A., Ludman, M., Dooley, J., Riddell, C. and Samuels, M. E. J Neurol Sci 2010; 1-2: 79-87. [BibTeX]

2009

  • Different models and single-nucleotide polymorphisms signal the simulated weak gene-gene interaction for a quantitative trait using haplotype-based and mixed models testing. Kovac, I. P. and Dubé, M. P. BMC Proc 2009: S77. [BibTeX]
  • The challenge of detecting epistasis (G x G interactions): Genetic Analysis Workshop 16. An, P., Mukherjee, O., Chanda, P., Yao, L., Engelman, C. D., Huang, C. H., Zheng, T., Kovac, I. P., Dubé, M. P., Liang, X., Li, J., de Andrade, M., Culverhouse, R., Malzahn, D., Manning, A. K., Clarke, G. M., Jung, J. and Province, M. A. Genet Epidemiol 2009: 58-67. [BibTeX]
  • Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Ross, C. J., Katzov-Eckert, H., Dubé, M. P., Brooks, B., Rassekh, S. R., Barhdadi, A., Feroz-Zada, Y., Visscher, H., Brown, A. M., Rieder, M. J., Rogers, P. C., Phillips, M. S., Carleton, B. C., Hayden, M. R., Hayden, M., Carleton, B., Ross, C., Smith, A., MacLeod, S., Wasserman, W., Hildebrand, C., Castro, L., Ghannadan, R., Carter, C., Honeyman, G., Katzov, H., Rassekh, R., Lau, L., Lim, J., Miao, F. et al. Nat Genet 2009; 12: 1345-1349. [BibTeX]
  • Association between cervical and intracranial dimensions and syringomyelia in the cavalier King Charles spaniel. Carruthers, H., Rusbridge, C., Dubé, M. P., Holmes, M. and Jeffery, N. J Small Anim Pract 2009; 8: 394-398. [BibTeX]
  • Application of principal component analysis to pharmacogenomic studies in Canada. Visscher, H., Ross, C. J., Dubé, M. P., Brown, A. M., Phillips, M. S., Carleton, B. C. and Hayden, M. R. Pharmacogenomics J 2009; 6: 362-372. [BibTeX]
  • Mutation in pyrroline-5-carboxylate reductase 1 gene in families with cutis laxa type 2. Guernsey, D. L., Jiang, H., Evans, S. C., Ferguson, M., Matsuoka, M., Nightingale, M., Rideout, A. L., Provost, S., Bedard, K., Orr, A., Dubé, M. P., Ludman, M. and Samuels, M. E. Am J Hum Genet 2009; 1: 120-129. [BibTeX]
  • Genetic modulation of brugada syndrome by a common polymorphism. Lizotte, E., Junttila, M. J., Dube, M. P., Hong, K., Benito, B., DE Zutter, M., Henkens, S., Sarkozy, A., Huikuri, H. V., Towbin, J., Vatta, M., Brugada, P., Brugada, J. and Brugada, R. J Cardiovasc Electrophysiol 2009; 10: 1137-1141. [BibTeX]
  • Application of homozygosity haplotype analysis to genetic mapping with high-density SNP genotype data. Jiang, H., Orr, A., Guernsey, D. L., Robitaille, J., Asselin, G., Samuels, M. E. and Dubé, M. P. PLoS One 2009; 4: e5280. [BibTeX]
  • Autosomal-dominant locus for Restless Legs Syndrome in French-Canadians on chromosome 16p12.1. Levchenko, A., Montplaisir, J. Y., Asselin, G., Provost, S., Girard, S. L., Xiong, L., Lemyre, E., St-Onge, J., Thibodeau, P., Desautels, A., Turecki, G., Gaspar, C., Dubé, M. P. and Rouleau, G. A. Mov Disord 2009; 1: 40-50. [BibTeX]
  • Genetic predictors of depressive symptoms in cardiac patients. McCaffery, J. M., Duan, Q. L., Frasure-Smith, N., Barhdadi, A., Lespérance, F., Théroux, P., Rouleau, G. A. and Dubé, M. P. Am J Med Genet B Neuropsychiatr Genet 2009; 3: 381-388. [BibTeX]

2008

  • D to the clinic. Phillips, M. S., Hihi, A. K., van Rooij, T., Smith, A. C., James, S., Marsh, S., Laplante, N., Dubé, M. P. and Tardif, J. C. Pharmacogenomics 2008; 10: 1391-1396. [BibTeX]
  • Mutations in the calcium-related gene IL1RAPL1 are associated with autism. Piton, A., Michaud, J. L., Peng, H., Aradhya, S., Gauthier, J., Mottron, L., Champagne, N., Lafrenière, R. G., Hamdan, F. F., Joober, R., Fombonne, E., Marineau, C., Cossette, P., Dubé, M. P., Haghighi, P., Drapeau, P., Barker, P. A., Carbonetto, S., Rouleau, G. A., Yang, Y., Laurent, S., Noreau, A., Henrion, E., Spiegelman, D., Diallo, O., Destroismaisons, L., Duguay, J., Kuku, F., Karemera, L., Côté, M. et al. Hum Mol Genet 2008; 24: 3965-3974. [BibTeX]
  • Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. de Denus, S., Zakrzewski-Jakubiak, M., Dubé, M. P., Bélanger, F., Lepage, S., Leblanc, M. H., Gossard, D., Ducharme, A., Racine, N., Whittom, L., Lavoie, J., Touyz, R. M., Turgeon, J. and White, M. Ann Pharmacother 2008; 7: 925-932. [BibTeX]
  • Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure. Zakrzewski-Jakubiak, M., de Denus, S., Dubé, M. P., Bélanger, F., White, M. and Turgeon, J. Br J Clin Pharmacol 2008; 5: 742-751. [BibTeX]
  • A novel locus for idiopathic generalized epilepsy in French-Canadian families maps to 10p11. Kinirons, P., Verlaan, D. J., Dubé, M. P., Poirier, J., Deacon, C., Lortie, A., Clément, J. F., Desbiens, R., Carmant, L., Cieuta-Walti, C., Shevell, M., Rouleau, G. A. and Cossette, P. Am J Med Genet A 2008; 5: 578-584. [BibTeX]
  • Anticonvulsant effects of leptin in epilepsy. Diano, S. and Horvath, T. L. J Clin Invest 2008; 1: 26-28. [BibTeX]

2007

  • Two-stage strategies to detect gene x gene interactions in case-control data. Barhdadi, A. and Dubé, M. P. BMC Proc 2007: S135. [BibTeX]
  • Multistage designs in the genomic era: providing balance in complex disease studies. Dubé, M. P., Schmidt, S., Hauser, E., Darabi, H., Li, J., Barhdadi, A., Wang, X., Sha, Q., Zhang, Z., Wang, T., Aschard, H., Guedj, M., Rohlfs, R., Anderson, A., Taylor, C., Mirea, L., Nickolov, R., Milanov, V., Yang, H. C., Song, Y. and Sinha, R. Genet Epidemiol 2007: S118-123. [BibTeX]
  • The genetics of congenital amusia (tone deafness): a family-aggregation study. Peretz, I., Cummings, S. and Dubé, M. P. Am J Hum Genet 2007; 3: 582-588. [BibTeX]
  • Mutations in the UBIAD1 gene, encoding a potential prenyltransferase, are causal for Schnyder crystalline corneal dystrophy. Orr, A., Dubé, M. P., Marcadier, J., Jiang, H., Federico, A., George, S., Seamone, C., Andrews, D., Dubord, P., Holland, S., Provost, S., Mongrain, V., Evans, S., Higgins, B., Bowman, S., Guernsey, D. and Samuels, M. PLoS One 2007; 8: e685. [BibTeX]
  • Syringomyelia in cavalier King Charles spaniels: the relationship between syrinx dimensions and pain. Rusbridge, C., Carruthers, H., Dubé, M. P., Holmes, M. and Jeffery, N. D. J Small Anim Pract 2007; 8: 432-436. [BibTeX]
  • Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. Xiong, L., Dion, P., Montplaisir, J., Levchenko, A., Thibodeau, P., Karemera, L., Rivière, J. B., St-Onge, J., Gaspar, C., Dubé, M. P., Desautels, A., Turecki, G. and Rouleau, G. A. Am J Med Genet B Neuropsychiatr Genet 2007; 7: 911-917. [BibTeX]
  • Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Goldberg, Y. P., MacFarlane, J., MacDonald, M. L., Thompson, J., Dube, M. P., Mattice, M., Fraser, R., Young, C., Hossain, S., Pape, T., Payne, B., Radomski, C., Donaldson, G., Ives, E., Cox, J., Younghusband, H. B., Green, R., Duff, A., Boltshauser, E., Grinspan, G. A., Dimon, J. H., Sibley, B. G., Andria, G., Toscano, E., Kerdraon, J., Bowsher, D., Pimstone, S. N., Samuels, M. E., Sherrington, R. and Hayden, M. R. Clin Genet 2007; 4: 311-319. [BibTeX]
  • Additive effects of obesity and TCF7L2 variants on risk for type 2 diabetes among cardiac patients. Duan, Q. L., Dubé, M. P., Frasure-Smith, N., Barhdadi, A., Lesperance, F., Théroux, P., St-Onge, J., Rouleau, G. A. and McCaffery, J. M. Diabetes Care 2007; 6: 1621-1623. [BibTeX]
  • Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans. Song, K., Dubé, M. P., Lim, J., Hwang, I., Lee, I. and Kim, J. J. Exp Mol Med 2007; 1: 114-120. [BibTeX]

2006

  • A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Levchenko, A., Provost, S., Montplaisir, J. Y., Xiong, L., St-Onge, J., Thibodeau, P., Rivière, J. B., Desautels, A., Turecki, G., Dubé, M. P. and Rouleau, G. A. Neurology 2006; 5: 900-901. [BibTeX]
  • A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3. Verlaan, D. J., Dubé, M. P., St-Onge, J., Noreau, A., Roussel, J., Satgé, N., Wallace, M. C. and Rouleau, G. A. J Med Genet 2006; 6: e31. [BibTeX]
  • Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. McCaffery, J. M., Frasure-Smith, N., Dubé, M. P., Théroux, P., Rouleau, G. A., Duan, Q. and Lespérance, F. Psychosom Med 2006; 2: 187-200. [BibTeX]
  • Human monogenic disorders - a source of novel drug targets. Brinkman, R. R., Dubé, M. P., Rouleau, G. A., Orr, A. C. and Samuels, M. E. Nat Rev Genet 2006; 4: 249-260. [BibTeX]
  • Autism spectrum disorders associated with X chromosome markers in French-Canadian males. Gauthier, J., Joober, R., Dubé, M. P., St-Onge, J., Bonnel, A., Gariépy, D., Laurent, S., Najafee, R., Lacasse, H., St-Charles, L., Fombonne, E., Mottron, L. and Rouleau, G. A. Mol Psychiatry 2006; 2: 206-213. [BibTeX]

2005

  • A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Duan, Q. L., Nikpoor, B., Dube, M. P., Molinaro, G., Meijer, I. A., Dion, P., Rochefort, D., Saint-Onge, J., Flury, L., Brown, N. J., Gainer, J. V., Rouleau, J. L., Agostoni, A., Cugno, M., Simon, P., Clavel, P., Potier, J., Wehbe, B., Benarbia, S., Marc-Aurele, J., Chanard, J., Foroud, T., Adam, A. and Rouleau, G. A. Am J Hum Genet 2005; 4: 617-626. [BibTeX]